Sera Prognostics (NASDAQ:SERA) Issues Earnings Results, Beats Estimates By $0.03 EPS

Sera Prognostics (NASDAQ:SERA) posted its earnings results on Thursday. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03, FiscalAI reports. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.10 million.

Sera Prognostics Price Performance

Shares of Sera Prognostics stock opened at $2.95 on Friday. The stock’s 50-day moving average is $3.16 and its 200 day moving average is $2.69. Sera Prognostics has a one year low of $1.37 and a one year high of $9.13. The firm has a market cap of $111.14 million, a price-to-earnings ratio of -3.47 and a beta of 0.97.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SERA. Wall Street Zen raised shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 21,158 shares of the stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $3.15, for a total transaction of $66,647.70. Following the transaction, the chief executive officer directly owned 811,136 shares in the company, valued at approximately $2,555,078.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 52,627 shares of company stock valued at $159,853 over the last quarter. 13.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of SERA. Qube Research & Technologies Ltd acquired a new position in Sera Prognostics during the 2nd quarter valued at about $92,000. Corient Private Wealth LLC raised its stake in shares of Sera Prognostics by 73.9% in the second quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock worth $277,000 after purchasing an additional 42,500 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Sera Prognostics by 4.6% in the third quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock valued at $3,725,000 after purchasing an additional 54,008 shares in the last quarter. Finally, Captrust Financial Advisors boosted its position in shares of Sera Prognostics by 20.0% during the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after buying an additional 100,366 shares during the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.